Dementia Associated With Alzheimer's Disease Market Research Report 2026: Overview of Over 80 Companies and More Than 100 Pipeline Drugs
Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "Dementia Associated With Alzheimer'S Disease - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.
The report provides a detailed overview of over 80 companies and more than 100 pipeline drugs targeting Dementia Associated With Alzheimer's Disease.
This comprehensive analysis includes drug profiles at various stages, from clinical to nonclinical, and evaluates therapeutics based on product type, development stage, administration route, and molecule type. Additionally, the report highlights inactive products within the landscape.
Global Coverage
Dementia, predominantly caused by Alzheimer's Disease (AD), manifests as a significant cognitive decline, leading to challenges in daily living activities. Characterized by amyloid-beta plaques and tau protein tangles, AD is genetically linked, especially involving mutations in APP, PSEN1, and PSEN2 genes. The genetic APOE ?4 allele is particularly associated with late-onset AD.
Diagnosis of AD-associated dementia involves comprehensive evaluations, including cognitive testing, neurological exams, and advanced imaging techniques to identify brain alterations. Despite the lack of a definitive cure, symptomatic treatments are available, primarily involving cholinesterase inhibitors and NMDA antagonists.
The report gives an expansive insight into the current scenario, including commercial assessments and detailed clinical evaluations of development-stage drugs. It discusses drug mechanisms, clinical studies, NDA approvals, technology platforms, collaborations, and market activities.
Key Highlights
The research outlines the strategic initiatives of companies aiming to address R&D challenges in Dementia Associated With Alzheimer's Disease through novel therapies. Drug development phases detail insights into specific stages like Phase II and III, highlighting pharmacological actions, collaborations, and recent breakthroughs.
Therapeutic Assessment and Development Activities
The report categorizes drugs by factors like development phase, route of administration (including intra-articular, intravenous, oral routes), and molecule types such as oligonucleotides and small molecules. It highlights ongoing therapeutic development, industry partnerships, mergers, acquisitions, and significant milestones.
Emerging Drug Candidates
Report Insights
Key Questions Addressed
Key Industry Players
Key Topics Covered:
Introduction
Executive Summary
Dementia Associated With Alzheimer's Disease: Overview
Pipeline Therapeutics
Therapeutic Assessment
Dementia Associated With Alzheimer's Disease- Analytical Perspective
Late Stage Products (Phase III)
Trontinemab: F. Hoffmann-La Roche Ltd.
Mid Stage Products (Phase II)
MK-1167: Merck & Co. / Neuphoria Therapeutics, Inc.
Early Stage Products (Phase I/II)
ARO-MAPT: Arrowhead Pharmaceuticals, Inc.
Preclinical and Discovery Stage Products
COYA 302: Coya Therapeutics, Inc/Dr. Reddy's Laboratories Ltd.
Inactive Products
Dementia Associated With Alzheimer's Disease Key Companies
Dementia Associated With Alzheimer's Disease Key Products
Dementia Associated With Alzheimer's Disease - Unmet Needs
Dementia Associated With Alzheimer's Disease - Market Drivers and Barriers
Dementia Associated With Alzheimer's Disease - Future Perspectives and Conclusion
Dementia Associated With Alzheimer's Disease Analyst Views
Dementia Associated With Alzheimer's Disease Key Companies
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/wmfcfu
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.